z-logo
Premium
Fecal metabolomics based on mass spectrometry to investigate the mechanism of qishen granules against isoproterenol‐induced chronic heart failure in rats
Author(s) -
Liu Shuxin,
Pi Zifeng,
Liu Zhiqiang,
Song Fengrui,
Liu Shu
Publication year - 2020
Publication title -
journal of separation science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.72
H-Index - 102
eISSN - 1615-9314
pISSN - 1615-9306
DOI - 10.1002/jssc.202000622
Subject(s) - heart failure , metabolomics , bile acid , metabolism , medicine , pharmacology , chemistry , metabolic pathway , pathogenesis , ursodeoxycholic acid , chromatography
Qishen granules, derived from clinical experience formula, has been widely used to improve and treat myocardial ischemic chronic heart failure in China. However, the mechanism of action of Qishen granules in the treatment of chronic heart failure is unclear. This study aimed to discover potential biomarkers of isoproterenol‐induced chronic heart failure rats and investigate the potential mechanism of Qishen granules treatment of chronic heart failure. The fecal metabolomics method based on ultra‐high‐performance liquid chromatography coupled with quadrupole time‐of‐flight mass spectrometry was used to analyze the therapeutic effect and metabolic changes of Qishen granules on chronic heart failure rats. Totally, 17 potential biomarkers were identified, involving bile acid metabolism, fatty acid metabolism, inflammatory response, and amino acid metabolism. For bile acid metabolism, we selected 12 bile acids (two of which were potential biomarkers in nontargeted metabolomics) for quantitative analysis. The quantitative results of bile acids showed that after Qishen granules treatment, the contents of bile acids such as ursodeoxycholic acid and glycodeoxycholic acid were similar to those of health group. This study helps to understand the pathogenesis of isoproterenol‐induced chronic heart failure and the therapeutic mechanism of Qishen granules from the perspective of metabolic pathways.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here